CD44 and non-small cell lung carcinoma: CD44+/CD24− cells were initially identified in breast tumors and breast-cancer-derived cell lines and have since been observed in the vast majority of tumors and tumor-derived cell lines, including non-small-cell lung carcinomas (NSCLCs), glioblastomas, neuroblastomas and leiomyosarcomas, as well as pancreatic, colon, prostate and ovarian tumors/cancers.